miquel lozano, md, phd dept. hemotherapy and hemostasis
TRANSCRIPT
![Page 1: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/1.jpg)
Bacterial contaminat ion of platelet concent rates
Miquel Lozano, MD, PhDDept . Hemotherapy and Hemostasis
University Clinic HospitalUniversity of Barcelona
Barcelona, Catalonia, Spain
![Page 2: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/2.jpg)
Disclosures
• Speaker honoraria from Cerus, Terumo BCT, Fresenius Kabi and Grífols• Research support from Terumo BCT, Sanofi-Genzyme and Maco Pharma• Member of advisory board for Grífols and Aenit is Technologies
![Page 3: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/3.jpg)
HBV, HCV and HIV Infect ious Risk per Transfused Unit
1/ 220,000
1/ 1,600,000
1/ 1,800,000
Bacterial contamination of PC
Bacterial sepsis fatalities PC
Bush MP, at al . JAMA 2003; 289: 959-62
![Page 4: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/4.jpg)
Bacterial Contaminat ion of Platelet Concent rates
• Incidence• Origin• Bacteria species• Clinical consequences• How to avoid it :
– Prevent– Detect– Inact ivate
![Page 5: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/5.jpg)
Incidence: depends on
• Method:– Bacterial culture – Oxygen consumpt ion
• Time of culture:– After preparat ion– At the end of storage
• Volume cultured• Culture medium
– Aerobic– Aerobic–Anaerobic
• Posit ive vs posit ive confirmed
![Page 6: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/6.jpg)
Benj amin RJ, Eder AF, Bacterial Contaminat ion of Platelet Products.In: Sweeney J, Lozano M, eds. Platelet Transfusion Therapy. AABB Press, 2013.
![Page 7: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/7.jpg)
Benj amin RJ, Eder AF, Bacterial Contaminat ion of Platelet Products.In: Sweeney J, Lozano M, eds. Platelet Transfusion Therapy. AABB Press, 2013.
![Page 8: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/8.jpg)
![Page 9: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/9.jpg)
Bacterial Contaminat ion of Platelet Concent rates
• Incidence• Origin• Bacteria species• Clinical consequences• How to avoid it :
– Prevent – Detect– Inact ivate
![Page 10: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/10.jpg)
Origin of the Contaminat ion
• Skin of the donor• Bacteremia in the donor• Contaminat ion during the collect ion or the process:
– Environment– Equipment
![Page 11: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/11.jpg)
Skin Anatomy
![Page 12: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/12.jpg)
Bacterial Contaminat ion of Platelet Concent rates
• Incidence• Origin• Bacteria species• Clinical consequences• How to avoid it :
– Prevent – Detect– Inact ivate
![Page 13: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/13.jpg)
Bacteria Ident if ied in apheresis platelets by aerobic day 1 culture. Screening performed 24 to 36 hours after collect ion, for 2004 to 2011, in the American Red Cross. A total of 681 confirmed-
posit ive cultures were detected from 3,426,573 apheresis platelet donat ions(1 de 5.031)
Bacterial Contaminants %Likely Skin Organisms
St aphylococcus, coagulase negat ive 42,3St aphylococcus aureus 7,8St reptococcus spp. 15,0Bacil lus spp. 2,2Other 1,8
Total 69,1Nonskin Organisms
St rept ococcus (agalact iae, bovis, pneumoniae,..) 10,6Escherichia col i 7,0Klebsiel la spp. 4,3Serrat ia marcescens 3,4List eria monocyt ogenes 1,5Ent erobact er spp. 1,3Ent erococcus ssp. 1,3Cit robact er spp. 0,4Pseudomonas spp. 0,3Salmonel la spp 0,3Other 0,6
Total 31,0
Benj amin RJ, Eder AF, Bacterial Contaminat ion of Platelet Products.In: Sweeney J, Lozano M, eds. Platelet Transfusion Therapy. AABB Press, 2013.
![Page 14: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/14.jpg)
Bacterial Contaminat ion of Platelet Concent rates
• Incidence• Origin• Bacteria species• Clinical consequences• How to avoid it :
– Prevent – Detect– Inact ivate
![Page 15: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/15.jpg)
Clinical Consequences
![Page 16: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/16.jpg)
Annual variation of the incidence of transfusion transmitted bacterial infection related to platelet concentrates
![Page 17: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/17.jpg)
Heinrich’ s Law
ht tps:/ / en.wikipedia.org/ wiki/ Herbert_Will iam_Heinrich
1 Accident with maj or inj ury
![Page 18: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/18.jpg)
Heinrich’ s Law
29 Accidents that cause minor inj uries
300 Accidents that cause no inj uries
ht tps:/ / en.wikipedia.org/ wiki/ Herbert_Will iam_Heinrich
1 Accident with maj or inj ury
![Page 19: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/19.jpg)
Relat ionship of bacterial species and bacterial load to occurrence and severit y of t ransfusion react ions in 45 cases, at the hospitals of the University of Cleveland,
Ohio, USA, between 1991 and 2006
Jakobs MR, et al . Clin Infect Dis. 2008;46:1214-1220
![Page 20: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/20.jpg)
Correlat ion of white blood count in pat ients who received bacterially contaminated platelets with presence or absence of sept ic t ransfusion react ion, at the hospitals of
the University of Cleveland, Ohio, USA, between 2007 y 2013
Hong H, et al . Blood 2016;127:496-502
![Page 21: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/21.jpg)
1/ 2,570
![Page 22: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/22.jpg)
Bacterial Contaminat ion of Platelet Concent rates
• Incidence• Origin• Bacteria• Clinical consequences• How to avoid it :
– Prevent – Detect– Inact ivate
![Page 23: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/23.jpg)
Prevent ion of Bacterial Contaminat ion
• Donor select ion• Donor arm disinfect ion technique • Diversion of the f irst mill il it ers of blood of the donat ion
![Page 24: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/24.jpg)
Diversion of the f irst 10 mL of the blood during donat ion
de Korte, D, et al . Vox Sang 2002;83:13-16
![Page 25: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/25.jpg)
Detect ion of the contaminated units
• Culture:– Bact -Alert®, Biomerieux
• Rapid test ing (Platelet PGD® test ) at the t ime of issuing the unit :– Gram posit ives: l ipoteichoic acid– Gran negat ives: l ipopolysaccharide
• Oxygen consumpt ion:– eBDS®, Pall
• Detect ion of bacteria using – Flow cytometry with f luorescent probes (Scansystem®)– 16S ribosomal RNA gene PCR
![Page 26: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/26.jpg)
1,004,206 units cultured 1:5,399 confirmed posit ives
20 sept ic t ransfusion react ions3 Fatalit ies 1:498,711
![Page 27: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/27.jpg)
ht tps:/ / www.fda.gov/ vaccines-blood-biologics/ guidance-compliance-regulatory-informat ion-biologics/ biologics-guidances
![Page 28: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/28.jpg)
ht tps:/ / www.fda.gov/ vaccines-blood-biologics/ guidance-compliance-regulatory-informat ion-biologics/ biologics-guidances
LVDS: large volume (≥ 16 mL), delayed sampling, inoculated evenly into aerobic and anaerobic culture media
![Page 29: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/29.jpg)
Pathogen inact ivat ion technologies for platelet concent rates approved in the European Union
• Amotosalen + ult raviolet A light , Intercept ® Blood System, Cerus Co. Approved in 2002
• Riboflavin + ult raviolet l ight , Mirasol® PRT, Terumo BCT. Approved in 2009
![Page 30: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/30.jpg)
Pathogen inact ivat ion: eff icacy against bacteria
Amotosalen Riboflavin
Irsch J, et al . Transfus Med Hemother 2011;38:19-31Marschner S, et al . Transfus Med Hemother 2011;38:8-18
![Page 31: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/31.jpg)
Cazenave JP, et al . Pathogen inact ivat ion of platelets. In: Sweeney J, Lozano M, eds. Platelet Transfusion Therapy. AABB Press, 2013
![Page 32: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/32.jpg)
Sept ic t ransfusion react ions (fatalit ies) per year before and after amotosalen implementat ion in Switzerland
Jutzi M, et al . Transfus Med Hemother 2018; 45:151–6
![Page 33: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/33.jpg)
Conclusions
• The safest blood components ever, however, st il l a signif icant risk of t ransfusion t ransmit ted bacterial infect ion by platelet t ransfusion
• In recent years several st rategies have been developed to reduce the risk of t ransmit t ing bacterial infect ions through platelet t ransfusion
• Pathogen inact ivat ion has been the only one that has shown it s eff icacy in eliminat ing completely the risk
![Page 34: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/34.jpg)
Thank you very much for your at tent ion!!
![Page 35: Miquel Lozano, MD, PhD Dept. Hemotherapy and Hemostasis](https://reader036.vdocument.in/reader036/viewer/2022081606/62c39584be575f14c2215d66/html5/thumbnails/35.jpg)